Great Valley Advisor Group
IMRX icon

Great Valley Advisor Group’s Immuneering IMRX Stock Holding History

Great Valley Advisor Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$77.8K Sell
19,120
-2,000
-9% -$9.45K ﹤0.01% 1066
2026
Q2 		$106K Hold
21,120
– – ﹤0.01% 1017
2026
Q1 		$112K Buy
21,120
+2,120
+11% +$10.9K ﹤0.01% 974
2025
Q4 		$125K Buy
+19,000
New +$122K ﹤0.01% 920

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Levin Capital Strategies
Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return

Great Valley Advisor Group's IMRX Position: Q3 2026 in Review

Great Valley Advisor Group reduced its Immuneering (IMRX) stake by 9.5% in Q3 2026, selling an estimated $9.45K and leaving 19,120 shares worth $77.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1066.

Great Valley Advisor Group first reported a position in IMRX in Q4 2025 and has held it in 4 quarters since. The position peaked at $125K in Q4 2025. 65 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Great Valley Advisor Group held 19,120 shares of Immuneering worth $77.8K as of Q3 2026.
  • Great Valley Advisor Group sold 2,000 Immuneering shares in Q3 2026, an estimated $9.45K.
  • Immuneering made up ﹤0.01% of Great Valley Advisor Group's portfolio in Q3 2026, its #1066 holding.
  • Great Valley Advisor Group first reported a position in Immuneering in Q4 2025 and has held it in 4 quarters since.
  • Great Valley Advisor Group's Immuneering position peaked at $125K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Great Valley Advisor Group's 13F filing for Q3 2026, filed 9 Nov 2026.